CYP4F3 and prostate carcinoma: Prostate cancer patients with low CYP4F3 gene expression showed a decreased cumulative survival of about 35% at about 130 months, whereas endometrial cancer patients with high CYP4F3 gene expression levels depicted a decreased cumulative survival of about 50% at 120 months.